MX2021014109A - Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1- fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida. - Google Patents

Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1- fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida.

Info

Publication number
MX2021014109A
MX2021014109A MX2021014109A MX2021014109A MX2021014109A MX 2021014109 A MX2021014109 A MX 2021014109A MX 2021014109 A MX2021014109 A MX 2021014109A MX 2021014109 A MX2021014109 A MX 2021014109A MX 2021014109 A MX2021014109 A MX 2021014109A
Authority
MX
Mexico
Prior art keywords
heart failure
isoxazol
fluoroethyl
difluoromethyl
pyrazol
Prior art date
Application number
MX2021014109A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Carlson
Jean-Francois Tamby
Chun Yang
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2021014109A publication Critical patent/MX2021014109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021014109A 2019-05-19 2020-05-18 Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1- fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida. MX2021014109A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US201962852739P 2019-05-24 2019-05-24
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Publications (1)

Publication Number Publication Date
MX2021014109A true MX2021014109A (es) 2021-12-10

Family

ID=70978663

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021014109A MX2021014109A (es) 2019-05-19 2020-05-18 Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1- fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida.
MX2025003918A MX2025003918A (es) 2019-05-19 2021-11-17 Tratamiento de la disfuncion sistolica

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025003918A MX2025003918A (es) 2019-05-19 2021-11-17 Tratamiento de la disfuncion sistolica

Country Status (16)

Country Link
US (2) US20220265629A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972597A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022535195A (cg-RX-API-DMAC7.html)
KR (1) KR20220009440A (cg-RX-API-DMAC7.html)
CN (1) CN114173782A (cg-RX-API-DMAC7.html)
AU (2) AU2020279710A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023074A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138080A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003045A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015505A2 (cg-RX-API-DMAC7.html)
IL (1) IL288051A (cg-RX-API-DMAC7.html)
MX (2) MX2021014109A (cg-RX-API-DMAC7.html)
PE (1) PE20220426A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112723PA (cg-RX-API-DMAC7.html)
TW (2) TW202541801A (cg-RX-API-DMAC7.html)
WO (1) WO2020236736A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210053939A1 (en) 2019-07-16 2021-02-25 MyoKardia, Inc. Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
WO2021052441A1 (zh) 2019-09-20 2021-03-25 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
JP7832128B2 (ja) * 2020-06-15 2026-03-17 マイオカーディア,インク 心房機能不全の治療
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP2014088342A (ja) * 2012-10-30 2014-05-15 Kowa Company Ltd ベンゾオキサジアゾール誘導体を有効成分とするmk2阻害剤
SG11201705928XA (en) * 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
WO2019006325A1 (en) * 2017-06-30 2019-01-03 Equalaire Systems, Inc. VENT CAP OF HUB CAP

Also Published As

Publication number Publication date
US20220265629A1 (en) 2022-08-25
PE20220426A1 (es) 2022-03-29
CA3138080A1 (en) 2020-11-26
TWI874399B (zh) 2025-03-01
KR20220009440A (ko) 2022-01-24
WO2020236736A1 (en) 2020-11-26
EP3972597A1 (en) 2022-03-30
JP2022535195A (ja) 2022-08-05
CN114173782A (zh) 2022-03-11
AU2025263744A1 (en) 2025-11-20
JP2025106475A (ja) 2025-07-15
SG11202112723PA (en) 2021-12-30
BR112021023074A2 (pt) 2022-03-29
TW202110449A (zh) 2021-03-16
CO2021015505A2 (es) 2021-12-10
US20250241903A1 (en) 2025-07-31
AU2020279710A1 (en) 2021-12-23
CL2021003045A1 (es) 2022-07-08
IL288051A (en) 2022-01-01
MX2025003918A (es) 2025-05-02
TW202541801A (zh) 2025-11-01

Similar Documents

Publication Publication Date Title
MX2025003918A (es) Tratamiento de la disfuncion sistolica
UY38160A (es) Partículas implantables y métodos relacionados
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
MX2021001957A (es) Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
ZA202204284B (en) Inhibitors of raf kinases
PH12018501414A1 (en) Composition and methods for cryopreservation of hutc
MY199353A (en) Methods of treatment using a jak inhibitor compound
CL2020002774A1 (es) Tratamiento combinado de fibrosis y/o angiogénesis ocular
CO2017012991A2 (es) Agonistas de triazol del receptor apj
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
NI201200016A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
MX2021005326A (es) Compuestos de pirimidinodiona contra estados cardiacos.
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
MX2022008018A (es) Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina.
MX2022015488A (es) Tratamiento para la disfuncion auricular.
CL2020001406A1 (es) Combinaciones herbicidas.
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
MX2019002615A (es) Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
LT3886799T (lt) Kompozicija, skirta plaukų slinkimo gydymui
CO2022000117A2 (es) Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.